急性髓系白血病细胞血管细胞黏附分子1、CD34和CD117的表达

背景：血管细胞黏附分子1与白血病浸润密切相关,白血病细胞本身是否表达血管细胞黏附分子1,以及与疾病难治是否相关尚无定论。目的：分析血管细胞黏附分子1、CD34、CD117在急性髓系白血病细胞表面的表达,3者之间的相互关系及与难治性急性髓系白血病的相关性。方法：采用流式细胞技术检测16例急性髓系白血病细胞中血管细胞黏附分子1、CD34、CD117的表达,其中难治组6例,非难治组10例;同时以正常骨髓单个核细胞标本作对照。结果与结论：急性髓系白血病细胞CD34、CD117表达高于对照组（P〈0.05）。难治组急性髓系白血病细胞CD34表达明显高于非难治组（P〈0.05）。难治组与非难治组CD117表达差异无显著性意义（P〉0.05）。急性髓系白血病细胞血管细胞黏附分子1表达与对照组比较差异无显著性意义（P〉0.05）。难治组与非难治组血管细胞黏附分子1表达差异无显著性意义（P〉0.05）。表明急性髓系白血病细胞伴CD34表达,为不良预后指标之一,CD117、血管细胞黏附分子1表达与其是否难治无明显相关性。

Expression of vascular cell adhesion molecule 1,CD34 and CD117 on acute myeloblastic leukemia cells

BACKGROUND：Vascular cell adhesion molecule 1（VCAM-1） is closely related to the infiltration of leukemia.The reports on whether leukemia cells can express VCAM-1 or not,and whether there is a relationship between refractory leukemia and VCAM-1 are inconclusive.OBJECTIVE：To study the expression of VCAM-1,CD34,CD117 on acute myeloid leukemia cells surface,investigate the relationship between them and the treatment effect of them on refractory acute myeloid leukemia.METHODS：The expression of VCAM-1,CD34,CD117 in acute myeloid leukemia cells from 16 patients were detected by flow cytometry.There were six patients in the refractory group and 10 patients in non-refractory group.Normal bone marrow mononuclear cells were regarded as control group.RESULTS AND CONCLUSION：The expressions of CD34 and CD117 on acute myeloid leukemia cells were higher than those in the control group（P 0.05）.The expression of acute myeloid leukemia cells CD34 in the refractory group was significantly higher than that in the non-refractory group（P 0.05）.There was no significant difference in CD117 expression on acute myeloid leukemia between refractory group and non-refractory group（P 0.05）.The expression of VCAM-1 on acute myeloid leukemia cells was not significantly different compared with the control group（P 0.05）.There was no significant difference in expression of VCAM-1 on acute myeloid leukemia between refractory group and non-refractory group（P 0.05）.Acute myeloid leukemia cells with CD34 expression is one of indices for poor prognosis and the expression of CD117 and VCAM-1 has no significant correlation with treatment of refractory acute myeloid leukemia.